Anika to Issue Third-Quarter 2018 Financial Results and Business Highlights on Wednesday, October 24

From Startup Anika Therapeutics

Link to Full Article: http://ir.anikatherapeutics.com/news-releases/news-release-details/anika-issue-third-quarter-2018-financial-results-and-business

BEDFORD, Mass.–(BUSINESS WIRE)–Oct. 10, 2018–
Anika
Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company
plans to issue its third-quarter 2018 financial results after the close
of the market on Wednesday, October 24, 2018 and hold its investor
conference call on the same day, Wednesday, October 24, 2018, at 5:00
p.m. ET to discuss its financial results, business highlights, and
outlook.

The conference call can be accessed by dialing 1-855-468-0611 (toll-free
domestic) or 1-484-756-4332 (international). A live audio webcast will
be available in the “Investor
Relations” section of Anika’s website, www.anikatherapeutics.com.
An accompanying slide presentation also can be accessed via the Anika
Therapeutics website. The call will be archived and accessible on the
same website shortly after its conclusion.

About Anika Therapeutics, Inc.
Anika
Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic
and regenerative medicines company based in Bedford,
Massachusetts. Anika is committed to improving the lives of patients
with degenerative orthopedic diseases and traumatic conditions with
clinically meaningful therapies along the continuum of care, from
palliative pain management to regenerative tissue repair. The Company
has over two decades of global expertise developing, manufacturing, and
commercializing more than 20 products based on its proprietary hyaluronic
acid (HA) technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC®,
MONOVISC®,
and CINGAL®,which
alleviate pain and restore joint function by replenishing depleted HA,
and HYALOFAST,
a solid HA-based scaffold to aid cartilage repair and regeneration. For
more information about Anika, please visit www.anikatherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181010005545/en/
Source: Anika Therapeutics, Inc.

For Investor Inquiries:Anika Therapeutics, Inc.Sylvia
Cheung, 781-457-9000Chief Financial OfficerorFor Media
Inquiries:Pure Communications, Inc.Sonal Vasudev,
917-523-1418sonal@w2ogroup.com

Please visit their site for more information: Anika Therapeutics.com

All,Biotechnology,Healthcare News,Startup News
2018-10-11 19:55:12